` Comparison: 300199 vs ROG - Alpha Spread

H
300199
vs
ROG

Over the past 12 months, Hybio Pharmaceutical Co Ltd has significantly outperformed ROG, delivering a return of +36% compared to the ROG's +11% growth.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
300199
ROG
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

Hybio Pharmaceutical Co Ltd Intrinsic Value
HIDDEN
Show
ROG Intrinsic Value
HIDDEN
Show
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
H
Hybio Pharmaceutical Co Ltd
SZSE:300199
16.41 CNY
Roche Holding AG
SIX:ROG
340.5 CHF
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
300199, ROG

300199
ROG
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
H
Hybio Pharmaceutical Co Ltd
Revenue
Roche Holding AG
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
300199, ROG

300199
ROG
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
H
Hybio Pharmaceutical Co Ltd
SZSE:300199
Roche Holding AG
SIX:ROG
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

Hybio Pharmaceutical Co Ltd
56.7%
ROG
73.9%

Operating Margin

Hybio Pharmaceutical Co Ltd
7%
ROG
35%

Net Margin

Hybio Pharmaceutical Co Ltd
-7.5%
ROG
20.9%

FCF Margin

Hybio Pharmaceutical Co Ltd
14.4%
ROG
17.7%

ROE

Hybio Pharmaceutical Co Ltd
-9.4%
ROG
39.3%

ROA

Hybio Pharmaceutical Co Ltd
-2.1%
ROG
12.7%

ROIC

Hybio Pharmaceutical Co Ltd
3.6%
ROG
19.4%

ROCE

Hybio Pharmaceutical Co Ltd
3.6%
ROG
29.2%

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
300199, ROG

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
300199, ROG

Performance Gap Between 300199 and ROG
HIDDEN
Show

Performance By Year
300199, ROG

Loading
300199
ROG
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare 300199 to other stocks
LLY
Eli Lilly and Co
More expensive
vs Hybio Pharmaceutical Co Ltd
JNJ
Johnson & Johnson
More expensive
vs Hybio Pharmaceutical Co Ltd
NOVN
Novartis AG
Cheaper
vs Hybio Pharmaceutical Co Ltd
AZN
AstraZeneca PLC
More expensive
vs Hybio Pharmaceutical Co Ltd
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett